Chugai Seiyaku Kabushiki Kaisha

The University of Tokyo

Other

Forerunner Pharma Research Co., Ltd.

Shigeto Kawai

Hiroyuki Aburatani

Naoki Kimura

Kiyotaka Nakano

Yasuo Koishihara

Shunpei Ishikawa

Tomoyuki Igawa

Masayuki Tsuchiya

Hiroyuki Tsunoda

Hirotaka Ito

Jun-Ichi Nezu

Yasuko Kinoshita

Masaaki Kosaka

Takahiro Ishiguro

Shumpei Ishikawa

Masahiko Mihara

Shuichi Tsutsumi

Masahiro Abe

Izumi Sugo

Kunihiro Nishimura

Shuji Ozaki

Takeshi Yoshino

Megumi Tanaka

Yasuo Koishibara

Hiroko Konishi

Shinichiro Iida

Hirofumi Sakumoto

Hiroyuki Tsundoa

Yasuo c/o Chugai Seiyaku Kabushiki K Koishihara

Kiyotaka c/o Chugai Seiyaki KK Nakano

Jun-Ichi c/o Chugai Seiyaki KK Nezu

Hiroyuki c/o Chugai Seiyaki KK Tsunoda

Takeshi c/o Chugai Seiyaki KK Yoshino

Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.

Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies

Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.

Diagnosis and treatment of cancer using anti-ITM2A antibody

A monoclonal antibody recognizing the extracellular region of LAMP5 was produced. The produced antibody demonstrated antibody-dependent cell-mediated cytotoxic activity, and/or cell growth inhibitory activity in the presence of a toxin-labeled secondary antibody, against a multiple myeloma cell line.

Anti-LAMP5 antibody and utilization thereof

An objective of the present invention is to provide chimeric receptors containing a mouse Fc&#x3b3; receptor extracellular domain and a human Fc&#x3b3; receptor transmembrane domain, or chimeric receptors containing a mouse Fc&#x3b3; receptor extracellular domain and a human &#x3b3; chain transmembrane domain. Another objective of the present invention is to provide methods for measuring the ADCC activity of mouse antibodies and methods of screening for mouse antibodies having ADCC activity, using the chimeric receptors. To accomplish the above-mentioned objectives, the present inventors produced chimeric molecules by fusing the extracellular domain of mouse Fc&#x3b3;R3 or mouse Fc&#x3b3;R4 with the transmembrane domain/intracellular domain of human &#x3b3; chain or human Fc&#x3b3;R3, and expressed the chimeric molecules in human NK92 cells. It was revealed that the ADCC activity can be induced by the chimeric receptors produced by any combination of the domains, and that the ADCC activity of mouse antibodies can be measured using the chimeric receptors of the present invention.

Chimeric Fc-gamma receptor and method for determination of ADCC activity by using the receptor

The present invention relates to an antibody binding to Claudin6 (CLDN6) expressed on a cell membrane. The antibody of the present invention recognizes human CLDN6 present in a native form on cell membrane surface and exhibits cytotoxicity through ADCC and/or CDC activities against cancer cell lines highly expressing human CLDN6. Moreover, the antibody of the present invention has cell growth inhibitory effect through conjugation with toxin on cancer cell lines highly expressing human CLDN6. The human CLDN6 is overexpressed in tumor tissues (lung adenocarcinoma, gastric cancer, and ovarian cancer), although its expression is not observed in normal tissues. Thus, the anti-CLDN6 antibody is expected to highly accumulate in tumors highly expressing human CLDN6 and can serve as a very effective antitumor agent.

Anti-CLDN6 antibody

The present invention relates to an antibody binding to a TM4SF20 protein and the diagnosis and treatment of cancer using the antibody. Specifically, the present invention provides an anti-TM4SF20 antibody and a pharmaceutical composition (e.g., an anticancer agent and a diagnostic drug for cancer) comprising the antibody as an active ingredient.

Diagnosis and treatment of cancer using anti-TM4SF20 antibody

Chimeric Fc&#x3b3; receptor and method for determination of ADCC activity by using the receptor

The present invention provides antibodies that bind to HS6ST2 proteins, pharmaceutical compositions comprising the antibodies as active ingredients, methods for diagnosing cancer using the antibodies, HS6ST2 proteins conjugated to cytotoxic agents and pharmaceutical compositions comprising the HS6ST2 proteins as active ingredients.

Anti-HS6ST2 antibodies and uses thereof

A therapeutic agent for solid tumors, the agent comprising as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence represented by SEQ ID NO:2 or an antibody fragment maintaining the antibody activity.

Therapeutic agents for solid tumors

To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. The results suggested that the 2D7 antigen is an HLA class I molecule. Based on this finding, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.

Cell death-inducing agent

An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.

Anti-glypican 3 antibody

The present invention is directed to a novel method for quantifying antigen, such as the amount expressed on a cell. The method comprises formulating an equation of correlation between the amount expressed of expressed antigen and the intensity of fluorescence from fluorescent labelled antibody.

Method of quantifying antigen expression

A method of detecting or determining plasmacytoma cells in a sample, said method comprising amplifying a polynucleotide that is specifically or strongly expressed in said plasmacytoma cells, and then detecting or measuring the amplified product.

Method for detection or measuring plasmocytoma cells

Growing community of inventors

Tokyo, Japan

Shigeto Kawai